Related Experiment Video
Updated: Dec 15, 2025
Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
Published on: August 16, 2024
Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from
Amélie Boichard1, Michael J Wagner2, Razelle Kurzrock3
1Center for Personalized Cancer Therapy, University of California, Moores Cancer Center, La Jolla, CA, 92093, USA. aboichard@ucsd.edu.
Background:
Angiosarcoma is an aggressive tumor. Recent case series describe exceptional responses to checkpoint blockade in this disease.
Methods:
Herein, we explored the genomic correlates of 48 angiosarcomas from the Angiosarcoma Project (12,499 variants analyzed in 6603 genes; whole-exome sequencing) versus 10,106 pan-cancer tumors in The Cancer Genome Atlas including 235 sarcomas but no angiosarcoma.
Results:
At the molecular level, angiosarcomas were heterogeneous. Those located in the face and scalp presented high tumor mutation burden, missense amino acid variations biased towards more hydrophobic (and therefore more immunogenic) peptides, and ultra-violet mutational signature.
Conclusions:
Angiosarcoma molecular features are similar to those observed in melanoma and other skin tumors and may explain comparable immunotherapy sensitivity of these tumor types.
Related Concept Videos
01:27Tumor Immunotherapy
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...